SAGE - Sage Therapeutics sees depression treatment zuranolone hitting the market as early as Q3

• Sage Therapeutics ( NASDAQ: SAGE ) said that its experimental oral therapy for major depressive disorder and postpartum depression, zuranolone, could become available as early as Q3.
• The company anticipates the US FDA will accept its rolling New Drug Application, completed in December , for the candidate in either Q1 or Q2, according to a presentation set to be made Tuesday morning at the J.P. Morgan Healthcare Conference.
• Sage ( SAGE ) noted that zuranolone fills an unmet medical need in depression as it provides rapid and sustained symptom relief, has a two-week treatment course, and uses a novel mechanism of action by targeting GABAaR, a neurotransmitter in the brain.
• Sage ( SAGE ) is partnered with Biogen ( BIIB ) and Shionogi ( OTCPK:SGIOF )( OTCPK:SGIOY ) on zuranolone.
• Read why Seeking Alpha contributor Clinically Sound investor, who rates Sage ( SAGE ) a hold, says that the company could be in store for a rocky review of zuranolone from the FDA .

For further details see: